Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022

SELL
$0.1 - $0.3 $461 - $1,384
-4,615 Reduced 9.35%
44,739 $5,000
Q2 2022

Aug 10, 2022

BUY
$0.24 - $0.39 $9,950 - $16,169
41,459 Added 525.13%
49,354 $16,000
Q1 2022

May 16, 2022

SELL
$0.28 - $0.41 $24,230 - $35,479
-86,536 Reduced 91.64%
7,895 $3,000
Q4 2021

Feb 14, 2022

BUY
$0.38 - $0.89 $35,876 - $84,025
94,411 Added 472055.0%
94,431 $36,000
Q2 2021

Aug 13, 2021

SELL
$1.06 - $2.25 $8,881 - $18,852
-8,379 Reduced 99.76%
20 $0
Q1 2021

May 12, 2021

SELL
$0.81 - $3.55 $3,708 - $16,255
-4,579 Reduced 35.28%
8,399 $17,000
Q4 2020

Feb 11, 2021

BUY
$0.72 - $1.52 $6,737 - $14,222
9,357 Added 258.41%
12,978 $10,000
Q3 2020

Nov 12, 2020

SELL
$0.92 - $2.4 $977 - $2,548
-1,062 Reduced 22.68%
3,621 $4,000
Q2 2020

Jul 31, 2020

BUY
$2.16 - $6.95 $10,115 - $32,546
4,683 New
4,683 $10,000

About Timber Pharmaceuticals, Inc.


  • Ticker TMBR
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,524,992
  • Description
  • Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to ...
More about TMBR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.